These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19954718)

  • 21. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
    Lee WL; Cheng MH; Tarng DC; Yang WC; Lee FK; Wang PH
    J Chin Med Assoc; 2013 Jul; 76(7):365-71. PubMed ID: 23664736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women.
    Chung YE; Lee SH; Lee SY; Kim SY; Kim HH; Mirza FS; Lee SK; Lorenzo JA; Kim GS; Koh JM
    Osteoporos Int; 2012 Apr; 23(4):1235-43. PubMed ID: 21660558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of raloxifene on bone turnover markers and bone mineral density in women on maintenance hemodialysis.
    Saito O; Saito T; Asakura S; Sugase T; Ito C; Ando Y; Muto S; Kusano E
    Clin Exp Nephrol; 2011 Feb; 15(1):126-31. PubMed ID: 21069410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raloxifene Prevents Early Periprosthetic Bone Loss for Postmenopausal Women after Uncemented Total Hip Arthroplasty: A Randomized Placebo-Controlled Clinical Trial.
    Gong L; Zhang YY; Yang N; Qian HJ; Zhang LK; Tan MS
    Orthop Surg; 2020 Aug; 12(4):1074-1083. PubMed ID: 32686337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of quantitative ultrasound measurements of bone for monitoring raloxifene therapy.
    Paggiosi MA; Clowes JA; Finigan J; Naylor KE; Peel NF; Eastell R
    J Clin Densitom; 2010; 13(4):441-50. PubMed ID: 20850365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis.
    Hong N; Shin S; Lee S; Kim KJ; Rhee Y
    Calcif Tissue Int; 2022 Jul; 111(1):47-55. PubMed ID: 35226133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of combined treatment with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis.
    Majima T; Komatsu Y; Shimatsu A; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    Endocr J; 2008 Mar; 55(1):127-34. PubMed ID: 18219181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.
    Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC
    Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low serum intact parathyroid hormone level is an independent risk factor for overall mortality and major adverse cardiac and cerebrovascular events in incident dialysis patients.
    Lee SA; Lee MJ; Ryu GW; Jhee JH; Kim HW; Park S; Jung SY; Oh HJ; Park JT; Han SH; Kang SW; Yoo TH
    Osteoporos Int; 2016 Sep; 27(9):2717-2726. PubMed ID: 27216997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.
    Cosman F; Keaveny TM; Kopperdahl D; Wermers RA; Wan X; Krohn KD; Krege JH
    J Bone Miner Res; 2013 Jun; 28(6):1328-36. PubMed ID: 23281041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D; Spencer CM
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
    Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography.
    Genant HK; Lang T; Fuerst T; Pinette KV; Zhou C; Thiebaud D; Diez-Perez A
    Bone; 2004 Nov; 35(5):1164-8. PubMed ID: 15542042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adherence to raloxifene therapy: assessment methods and relationship with efficacy.
    Finigan J; Naylor K; Paggiosi MA; Peel NF; Eastell R
    Osteoporos Int; 2013 Nov; 24(11):2879-86. PubMed ID: 23695420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone turnover markers predict type of bone histomorphometry and bone mineral density in Asian chronic haemodialysis patients.
    Laowalert S; Khotavivattana T; Wattanachanya L; Luangjarmekorn P; Udomkarnjananun S; Katavetin P; Eiam-Ong S; Praditpornsilpa K; Susantitaphong P
    Nephrology (Carlton); 2020 Feb; 25(2):163-171. PubMed ID: 30980579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raloxifene slows down the progression of intima-media thickness in postmenopausal women.
    Colacurci N; Fornaro F; Cobellis L; De Franciscis P; Torella M; Sepe E; Arciello A; Cacciapuoti F; Paolisso G; Manzella D
    Menopause; 2007; 14(5):879-84. PubMed ID: 17667145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.